InsidersTradesSigma
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the complete record of transactions filed by Myers Scott Dunseth. Director active across 4 companies, notably Viridian Therapeutics, Inc.\DE. Cumulatively, 15 disclosures have been recorded. Split: 3 buys · 0 sell. Total volume traded: €268k. History available since 6 February 2023. The latest transaction was disclosed on 17 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations
Myers Scott Dunseth is a declarant linked to Harpoon Therapeutics, Inc., Viridian Therapeutics, Inc.\DE, Zentalis Pharmaceuticals, Inc. and Dynavax Technologies CORP, with the listed role of Director at Harpoon Therapeutics, Inc. and Zentalis Pharmaceuticals, Inc., and Chief Executive Officer at Viridian Therapeutics, Inc.\DE. Across 13 filings in total, the sampled filings, from 2023-02-07 to 2025-04-30, show buy transactions of EUR 268256 and no sell transactions reported.